melanotan 2020 Exposed: Facts, Fiction, and Safety Concerns Melanotan II | | 121062-08-6

Disclosure of interest: Nothing to disclose Poster Session I - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P412 - ESOC25-2081 THE CURRENT STATUS, DECISION MAKING AND EFFECTIVENESS OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ISCHEMIC STROKE IN CHINA Xiaoqing Jiang 1 , Zixiao Li 1,2,3 , Yongjun Wang 1,2,3 1 Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, 2 China National Clinical Research Center for Neurological Diseases, Beijing, China, 3 National Center for Healthcare Quality Management in Neurological Diseases, Beijing, China Background and Aims: In real-world settings, the application scope of dual antiplatelet therapy (DAPT) for acute ischemic stroke (AIS) is more extensive than that of randomized controlled trials (RCTs)

JT: Conceptualization, Funding acquisition, Investigation, Writing review & editing

Receive your personalized Melanotan-2 protocol with loading phase instructions, maintenance dosing, and UV exposure guidelines

Mechanism of action Cellular Signaling Activation : Peptides bind to specific receptors, triggering intracellular pathways that regulate growth, repair and metabolism

Prokinetics in the Management of Functional Gastrointestinal Disorders